Dare Bioscience Amends Bylaws to Lower Stockholder Meeting Quorum to One-Third
Dare Bioscience, Inc.
Subscribe to track DARE
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Dare Bioscience Amends Bylaws to Lower Stockholder Meeting Quorum to One-Third
Company: Dare Bioscience, Inc. (DARE)
Form: 8-K | Filed: 2026-09-11
Significance: Low
Event Summary: • Item 5.03: Amendment to By-Laws • Action: Effective September 10, 2026, the Board amended Section 1.6 of Article I of the By-Laws to reduce the quorum requirement for stockholder meetings from a majority to at least one-third (33.33%) of the voting power of outstanding shares.
Key Insight: Lowering the quorum threshold simplifies holding annual and special meetings, a standard operational adjustment often seen in micro-cap companies with diffuse retail ownership.
Market Context: With a market capitalization of approximately $10M and 14.98M shares outstanding, achieving a 50% voting quorum can be challenging and costly.
Comprehensive Analysis
SEC Filing Analysis: Dare Bioscience, Inc. (DARE)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Dare Bioscience amended its bylaws to reduce the stockholder meeting quorum requirement from a majority to one-third of outstanding voting power.
- Market Impact: Neutral; this is an administrative governance modification with no immediate financial or operational impact.
Company Information
| Field | Value |
|---|---|
| Company | Dare Bioscience, Inc. |
| Ticker Symbol | DARE |
| CIK | 0001401914 |
| Industry | Pharmaceutical Preparations [2834] |
Filing Summary
| Field | Value |
|---|---|
| Form Type | 8-K |
| Item Reported | Item 5.03: Amendments to Articles of Incorporation or Bylaws |
| Effective Date | September 10, 2026 |
| Accession Number | 0001401914-26-000050 |
Event Details & Governance Context
On September 10, 2026, the Board of Directors of Dare Bioscience, Inc. approved an amendment to its Third Amended and Restated By-Laws. The amendment alters Section 1.6 of Article I to reduce the required quorum for meetings of stockholders from a majority of the voting power of issued and outstanding shares to at least one-third (33.33%).
Strategic & Capital Structure Context
- Market Capitalization Context: Dare Bioscience operates as a micro-cap biopharmaceutical company (~$10M market cap across ~14.98M shares outstanding).
- Rationale: Micro-cap companies with substantial retail shareholder bases often struggle to achieve 50% quorum thresholds due to lower voter participation, frequently necessitating expensive solicitation efforts or adjournments. A one-third quorum requirement is compliant with Delaware General Corporation Law (DGCL § 216) and streamlines annual meeting governance.
Market Impact Analysis
- Stock Impact Prediction: Neutral. Bylaw quorum changes do not alter underlying corporate fundamentals, balance sheet strength, or clinical pipeline progress.
- Volume & Sentiment: Expected volume impact is negligible, and market sentiment remains unaffected.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.